Medicare is set to negotiate prices for Ozempic and Wegovy starting in 2027, aiming to reduce costs after their inclusion under the Inflation Reduction Act.
While it is uncertain how much prices will fall for these weight-loss medications, past negotiation outcomes suggest potential cuts might be minimal, resulting in limited savings for the government.
The Biden administration's initiative to expand coverage for obesity drugs could increase federal spending, depending on if the incoming Trump administration will continue this proposal.
Ozempic and Wegovy, produced by Novo Nordisk, are transforming obesity treatment yet remain largely inaccessible to many due to high out-of-pocket costs and lack of insurance coverage.
Collection
[
|
...
]